Stock data
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM) reported net income of -US$219.88M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$241.65M | -US$219.88M | — |
| 2024 | — | — | -US$196.92M | -US$167.38M | — |
| 2023 | — | — | -US$191.09M | -US$153.16M | — |
| 2022 | US$0.00M | — | US$144.65M | US$111.21M | — |
| 2021 | US$18.94M | — | -US$67.95M | -US$65.57M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$53.70M | — |
| 2026-03-31 | — | -US$49.66M | — |
| 2025-12-31 | — | -US$50.71M | — |
| 2025-09-30 | — | -US$50.61M | — |
| 2025-06-30 | — | -US$70.06M | — |
| 2025-03-31 | — | -US$48.50M | — |
| 2024-12-31 | — | -US$47.65M | — |
| 2024-09-30 | — | -US$40.56M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.